Table of Content

Open Access iconOpen Access

ARTICLE

Cross validation of the prostate cancer radiotherapy late toxicity (PCRT) questionnaire with the expanded prostate cancer index composite (EPIC) instrument

George Rodrigues1,2, Glenn Bauman1, Varagur Venkatesan1, Belal Ahmad1, Michael Lock1, Tracy Sexton1, David D’Souza1, Larry Stitt2, Somaya Eid1,2

1 Department of Radiation Oncology, London Regional Cancer Program, London Health Sciences, London, Ontario, Canada
2 Department of Epidemiology and Biostatistics, University of Western Ontario, London, Ontario, Canada
Address correspondence to Dr. George Rodrigues, Department of Radiation Oncology, London Regional Cancer Program, A3-808 790 Commissioners Road East, London Ontario N6A 4L6 Canada

Canadian Journal of Urology 2011, 18(4), 5802-5810.

Abstract

Introduction: A 29-item prostate cancer radiotherapy (PCRT) questionnaire with genitourinary (GU), gastrointestinal (GI), and sexual (S) domains has been previously validated for the assessment of late toxicity health-related quality of life (HRQoL) effects. The study objective was to cross-validate the PCRT domains versus the expanded prostate cancer index composite (EPIC) questionnaire urinary (U), bowel (B), hormonal (H), and S subscales.
Methods and materials: A single-institution cross-sectional PCRT patient cohort was surveyed. Descriptive and intra- and inter-class correlation coefficient statistics for the various EPIC and PCRT HRQoL domain scores were generated. Univariable and multivariable Cox and logistic regressions were performed depending on the HRQoL endpoint being assessed.
Results: A total of 189/276 patients (68%) completed questionnaires with EPIC and PCRT missing data rates of 9% and 4%, respectively. Mean age was 75.8 years (SD 5.5) and the mean time of questionnaire completion after radiotherapy was 852 days (range 212-1454 days). Mean EPIC urinary (85.1 SD 12.9), bowel (84.1 SD 15.8), sexual (21.8 SD 20.7), and hormonal (85.3 SD 13.7) as well as PCRT genitourinary (66.1 SD 15.3), gastrointestinal (83.6 SD 14.3), and sexual (39.4 SD 21.6) domain scores were calculated. Intraclass correlation coefficients comparing corresponding EPIC/PCRT domains ranged from 0.50-0.88. Interclass correlation coefficients for non-corresponding EPIC/PCRT domains ranged from 0.16-0.43 and 0.23-0.30, respectively. EPIC B/U, PCRT GI/GU and PCRT S required arcsin square root transformation and EPIC S/H domains required dichotomous transformations prior to univariable/multivariable analyses. Multivariable analysis demonstrated novel associations between predictive variables and HRQoL domains including between the PTV-bladder overlap volume and PCRT GU score.
Conclusions: The PCRT is a compact, valid, and HRQoL instrument with very high questionnaire compliance rates and similar statistical properties to the EPIC instrument. However, dichotomization of the PRCT S data was not required which suggests some potential statistical advantage to the PCRT.

Keywords

prostate cancer, health-related quality-of-life, cross-validation, late toxicity, radiotherapy

Cite This Article

APA Style
Rodrigues, G., Bauman, G., Venkatesan, V., Ahmad, B., Lock, M. et al. (2011). Cross validation of the prostate cancer radiotherapy late toxicity (PCRT) questionnaire with the expanded prostate cancer index composite (EPIC) instrument. Canadian Journal of Urology, 18(4), 5802–5810.
Vancouver Style
Rodrigues G, Bauman G, Venkatesan V, Ahmad B, Lock M, Sexton T, et al. Cross validation of the prostate cancer radiotherapy late toxicity (PCRT) questionnaire with the expanded prostate cancer index composite (EPIC) instrument. Can J Urology. 2011;18(4):5802–5810.
IEEE Style
G. Rodrigues et al., “Cross validation of the prostate cancer radiotherapy late toxicity (PCRT) questionnaire with the expanded prostate cancer index composite (EPIC) instrument,” Can. J. Urology, vol. 18, no. 4, pp. 5802–5810, 2011.



cc Copyright © 2011 The Author(s). Published by Tech Science Press.
This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 145

    View

  • 109

    Download

  • 0

    Like

Share Link